Cas9 gene-edited HSC therapy (Editas Medicine)

N/A

Report date: 2025/10/21 15:42:24

Base Information

Drug NameCas9 gene-edited HSC therapy (Editas Medicine)
Drug Alias Nameex-vivo Cas9 gene-edited HSC therapyCRISPR-Cas9 gene-edited HSC therapy
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEditas Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine IncVor Biopharma Inc
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A